Updates

April 22, 2019April 22, 2019
Simponi or Remicade Treatment Lowers Healthcare Use, Increases Work Productivity in AS Patients, Study Says

A six-month course of treatment with Janssen‘s Simponi (golimumab) or Remicade (infliximab) significantly reduced the use of healthcare resources and increased work ... Read more
April 18, 2019April 18, 2019
AS Patients More Likely to Develop Venous Thromboembolism, Study Says

Patients with ankylosing spondylitis are more likely to develop venous thromboembolism — a condition in which a blood clot that forms in a vein can ... Read more
April 17, 2019April 16, 2019
Finding Balance on Social Media While Managing Chronic Illness

There are many great things about social media. It connects people who would never otherwise meet or talk, creates shared experiences, and can be ... Read more
April 15, 2019April 15, 2019
Stopping Infliximab Can Cause Relapses in Ankylosing Spondylitis Patients, Study Says

Stopping treatment with infliximab (brand names, Remsima, Remicade) can lead to relapses in people with ankylosing spondylitis (AS) who are in stable clinical remission, ... Read more
April 11, 2019April 11, 2019
Kidney Issues Should be Considered While Using TNF-Alpha Inhibitors

Despite being rare, kidney complications should be considered in patients with ankylosing spondylitis treated with inhibitors of tumor necrosis factor-alpha (TNF-alpha), such as ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

News

Higher Serum BMP-2 Levels may be Linked to the Development of Ankylosing Spondylitis, Meta-Analysis Shows
April 8, 2019April 8, 2019
While serum levels of sclerostin — a protein that regulates bone formation — are identical in ...
News

Simponi Aria Shows Signs of Efficacy in Patients with Active Ankylosing Spondylitis
April 4, 2019April 4, 2019
Treatment with Simponi Aria (golimumab) for one year reduced the signs and symptoms of ankylosing ...
A Wellness Journey - a Column by Lisa Marie Basile, Columns

How Stress Impacted My Ankylosing Spondylitis
March 27, 2019March 25, 2019
When I was officially diagnosed with ankylosing spondylitis (AS) two years ago, I’d been ...
News

High Chitotriosidase Levels Linked to Ankylosing Spondylitis Activity
March 25, 2019March 25, 2019
High levels of the protein chitotriosidase in the blood are associated with more disease activity ...
News

Study Examines Differences in Gut Contents of Male, Female Ankylosing Spondylitis Patients
March 20, 2019March 20, 2019
Gender-based differences in fecal metabolites in ankylosing spondylitis patients may provide clues about differences ...
News

Diet, Air Pollution May Play Role in Ankylosing Spondylitis Activity, Study Suggests
March 18, 2019March 18, 2019
A high-fat diet and long-term exposure to air pollution are both associated with worse ...

Brexit Could Have Real Effects for UK Rare Disease Patients, Experts Warn
March 14, 2019
Madeline Collin, a 24-year-old activist with Gaucher disease, worries that patients like her will ...
Anti-TNF Alpha Therapy Improves Exercise Capacity After Four Months of Treatment, Study Suggests
March 13, 2019March 13, 2019
Anti-TNF alpha therapy is able to significantly restore ankylosing spondylitis patients’ capacity to exercise after ...
My Shingles Story: How It Happened and What I Did in Response
March 13, 2019March 12, 2019
High Levels of C-reactive Protein Can Predict Risk for Future Ankylosing Spondylitis, Study Finds
March 6, 2019March 6, 2019
NIH Rare Disease Day Highlights Joint Networks Advancing Array of Research
March 6, 2019March 5, 2019
Anti-TNF-Alpha Therapies Linked to Reduced Lumbar Spine Deformities, Study Shows
March 4, 2019March 4, 2019

Ankylosing Spondylitis Patients Have Higher Risk of Blood Clots, Study Suggests
February 27, 2019March 27, 2019
Ankylosing spondylitis (AS) patients have a more than 50% increased risk of developing blood ...
3 Ways to Get Out of an Ankylosing Spondylitis Slump
February 27, 2019February 26, 2019
WODC 2019 Organizers Expect 1,200 to Attend Rare Disease Conference in April
February 25, 2019February 25, 2019
Vienna to Host RARE2019 Meeting on Rare Diseases
February 25, 2019February 20, 2019

What Ankylosing Spondylitis Taught Me About Myself
February 20, 2019February 19, 2019
Getting diagnosed with ankylosing spondylitis (AS) wasn’t just about figuring out (finally!) which disease ...
Plant Compound Emodin Could be Used as Treatment for AS, Study Says
February 18, 2019February 18, 2019
Tiny RNA Molecule a Potential Diagnostic Biomarker for Ankylosing Spondylitis, Study Says
February 13, 2019February 13, 2019

A Wellness Journey - a Column by Lisa Marie Basile, Columns

How to Stay Informed About Ankylosing Spondylitis
February 13, 2019February 12, 2019
I’m a wellness writer and editor. Some of my work has appeared in publications ...
News

Risk for Dementia Higher in Ankylosing Spondylitis Patients, Study Suggests
February 11, 2019February 11, 2019
The risk for developing overall dementia and Alzheimer’s disease dementia is higher in patients ...
News

Patients, Family and Friends to Take Part in Variety of Rare Disease Day Events Worldwide
February 11, 2019
Scores of events are afoot worldwide to mark Feb. 28, Rare Disease Day 2019. The activities ...
News

Two Bone Metabolism-related Proteins May Help Determine Ankylosing Spondylitis Risk, Study Suggests
February 6, 2019February 6, 2019
Determining blood levels of two proteins — osteoprotegerin (OPG) and receptor activator of nuclear ...
News

TNF Inhibitors Improve Bone Mineral Density but Not Vertebral Fractures in AS Patients, Study Says
February 4, 2019February 4, 2019
Long-term treatment with TNF-alpha inhibitors improves bone mineral density (BMD) but does not affect ...
News

Levels of RNA Molecule a Potential Biomarker for Ankylosing Spondylitis, Study Suggests
January 30, 2019January 30, 2019
Analyzing the circulating levels of a specific RNA molecule, known as MEG3, may be used as ...

March 7, 2018March 7, 2018

Cosentyx Leads to Long-Term Improvement in AS Patients, Phase 3 Trial Shows

News

Results from a Phase 3 clinical trial show that treatment with Cosentyx (secukinumab) led to fast, significant, and sustained symptom improvement in patients with active ankylosing spondylitis (AS). Improvements were particularly noticeable in patients who had never ... Read more

Subscribe to our mailing list

Pin It on Pinterest